INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• Key Takeaways And Market Insights From The Inaugural ThinkLive Summit

  The inaugural ThinkLive Cell and Gene Therapy Summit explored the industry’s dynamic landscape, highlighting collaboration, communication, and market access challenges.

• Advertising & Promotional Review Consulting

  ProPharma has built the world’s leading and first full-service global solution dedicated to Advertising & Promotional Review. 

• Strategic Considerations For Success In Gene-Based Therapeutics Development

  The forces that impact gene therapy development continue to evolve dramatically. This paper explores strategic considerations for regulatory, operational, and commercial success.

• CRISPR And The Commercialization Of Gene-Based Therapies

  The importance of early collaboration between drug developers, manufacturers, and payers is becoming more evident, as it aids in the creation of meaningful clinical endpoints and the formulation of a viable market access strategy.

• Ways To Enhance Access To Cell Therapies

  Cell therapies are revolutionizing cancer care, but their complex manufacturing and high costs bar access for many patients. Automation is emerging as an efficacious solution to reach patients in need.

• Takeaways From Cencora's Inaugural Cell And Gene Therapy Summit

  Collaboration, communication, and competition are key to advancing cell and gene therapy. Experts share insights from Cencora's inaugural CGT summit.

• Digital Transformation In Life Sciences: The Importance Of Data Strategy

  Learn how to align data with business objectives, ensure clean and contextualized data, and establish comprehensive data standards and governance with a robust data strategy.

• Bringing A Device From Concept To Market

  Within three years, see how this company was able to achieve FDA approval and CE Marking, facilitating its entry into the U.S. and EU markets.

• Identifying Drug Development Opportunities For DMD With CureDuchenne

  Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene therapies for Duchenne muscular dystrophy (DMD).

• CGT Expert Consulting Team

  At ProPharma, our Cell and Gene Therapy consulting team offers a comprehensive and integrated approach to early stage cell and gene therapy development. Our expert team provides a range of services, including IND/CTA preparation, manufacturing technology, safety and risk assessment, and development planning, to help our clients navigate the complex and ever-changing landscape of cell and gene therapy development.